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Jens-R. Allenberg, MD, PhD,a Heidelberg, Germany
Objective: To evaluate limb-salvage surgery with vascular resection for lower extremity soft tissue sarcomas (STS) in adult
patients and to classify blood vessel involvement.
Methods: Subjects were consecutive patients (median age, 56 years) who underwent vascular replacement during surgery
of STS in the lower limb between January 1988 and December 2003. Blood vessel involvement by STS was classified as
follows: type I, artery and vein; type II, artery only; type III, vein only; and type IV, neither artery nor vein (excluded from
the analysis). Patient data were prospectively gathered in a computerized database.
Results: Twenty-one (9.9%) of 213 patients underwent vascular resections for lower limb STS. Besides 17 type I tumors
(81.0%), 3 (14.3%) type II and 1 (4.7%) type III STS were diagnosed. Arterial reconstruction was performed for all type
I and II tumors. Venous replacement in type I and III tumors was performed in 66.7% of patients. Autologous vein
(n  8) and synthetic (Dacron and expanded polytetrafluoroethylene; n  12) bypasses were used with comparable
frequency for arterial repair, whereas expanded polytetrafluoroethylene prostheses were implanted in veins. Morbidity
was 57.2% (hematoma, thrombosis, and infection), and mortality was 5% (embolism). At a median follow-up of 34
months, the primary and secondary patency rates of arterial (venous) reconstructions were 58.3% (54.9%) and 78.3%
(54.9%). Limb salvage was achieved in 94.1% of all cases. The 5-year local control rate and survival rate were 80.4% and
52%, respectively. We observed a 5-year metastasis-free survival rate of 37.7% and found vessel infiltration and higher
tumor grade (low-grade vs intermediate grade and high grade tumors) to be negative prognostic factors at univariate and
multivariate analysis.
Conclusions: Long-term bypass patency rates, the high percentage of limb salvage, and the oncologic outcome underline
the efficacy of en bloc resection of STS involving major vessels in the lower limb. Disease-specific morbidity must be
anticipated. The classification of vascular involvement (type I to IV) is useful for surgical management. (J Vasc Surg
2005;42:88-97.)Function-sparing resection has become the standard
recommended surgical treatment for lower limb soft tissue
sarcomas (STS).1-4 Local tumor control is related to the
type of resection and whether patients received adjuvant
radiotherapy.4-6 Complete resection improves both local
tumor control and survival.6-8 However, STS that involve
vascular structures remain a crucial issue.
If STS arise from arterial or venous blood vessels, then
vascular resection is inevitable.9-16 Furthermore, if STS
infiltrate or surround vascular structures, then the vessels
must also be resected to meet established procedural stan-
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88dards.1,2,17-27 STS surrounded by a plane of normal tissue
can be dissected from major blood vessels. By longitudi-
nally splitting the adventitia opposite the tumor, a rim of
normal tissue is preserved in the vessel-tumor inter-
face.27,28 Vascular resection, however, increases the width
of the resection margin.26,27 Therefore, it was proposed
that whenever it is impossible to achieve a wide resection
margin without vascular resection, vascular resection is
indicated.26,27
Only few published studies have reported the outcome
of limb-sparing of STS surgery with blood vessel replace-
ment, and to our knowledge, only two series includedmore
than ten patients.17-27 Furthermore, blood vessel involve-
ment has not been systematically classified, nor has a treat-
ment algorithm been suggested. The aim of this study was
to classify vascular involvement by extremity STS, to sug-
gest a treatment algorithm, and to analyze the results of
limb-sparing surgery necessitating vascular resection.
METHODS
Selection of patients. Consecutive adult patients in
whom STS involved major arterial or venous blood vessels
in the lower extremity and who were treated by limb-
preserving resection between January 1988 and December
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here. Patients were identified from a prospectively gathered
database containing prospective data from all patients with
STS treated during this period. Patients were diagnosed
with STS (color duplex sonography, magnetic resonance
[MR] imaging, computed tomography [CT], angiography,
or a combination of these) arising in a major blood vessel or
extending toward a major blood vessel in the lower extrem-
ity. Vascular involvement was diagnosed when MR or CT
imaging did not show a rim of normal tissue in the tumor-
to-vessel interface. The indications for vascular resection
were standardized. Patients underwent vascular resection
when STS were of primary vascular origin (primary vascular
involvement) or were infiltrating, encasing, or affecting
major blood vessels (secondary vascular involvement).
Classification of vascular involvement. Types of vas-
cular involvement were assessed before surgery by high-
resolution CT or MR imaging. STS involving both major
arteries and veins were classified as type I. STS affecting
only arterial blood vessels were classified as type II. Sarco-
mas involving major veins without altering an artery were
classified as type III. STS without involvement of arterial or
venous blood vessels were classified as type IV (Fig 1).
Surgery, radiation, and vascular replacement. STS
were resected en bloc together with blood vessels according
to the type of vascular involvement and the surgical stan-
dards described by Enneking et al.1,2 Neural structures
were included in the en bloc specimen if they were encased
or infiltrated by the tumor. One pathologist (G.M.) as-
sessed the resected specimens for infiltration of the blood
vessel wall, tumor grade, and microscopic margin. Grade
was determined by the degree of cellularity, differentiation,
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1) were excluded. Therefore, data from 21 patients were
analyzed, giving a 9.9% rate of vascular resections in the
group of lower extremity STS (n  213). The median age
of the patients was 56 years (interquartile range [IQR],
32-75 years). Swelling (n  18), pain (n  9), and neuro-
logic disorders (n 2) were observed. Most of the patients
were referred for primary STS. Two patients were diag-
nosed with the first, two with the second, one with the
third, and one with the fifth local recurrence. A total of 19
(90%) patients were treated for locally advanced STS with-
out concomitant metastatic disease, and 2 (10%) patients
were treated for locally advanced STS with distant disease.
Liposarcoma was the predominant histopathologic diagno-
sis, and higher-grade (intermediate grade and high grade)
tumors were found in 62% of the patients. In most STS
(90%), secondary involvement of blood vessels was ob-
served, whereas two STS originated in the wall of the blood
vessel. Sixty-five percent of the patients received adjuvant
radiation therapy. The clinicopathologic data are summa-
rized in Table I.
Arterial reconstruction. In four patients, iliofemoral
repair was performed; this repair consisted of two ePTFE
prostheses (8 mm), one Dacron bypass graft (8 mm), and
one autologous vein graft. In one of these patients, the
deep femoral artery was ligated. One iliocrural (anterior
tibial artery) reversed venous bypass (extra-anatomic) was
implanted after extensive compartmental resection. Femo-
Table I. Clinicopathologic factors in 21 patients with
soft tissue sarcomas of the lower extremity involving
major blood vessels*
Characteristic No. (N  21) %
Sex
Male 10 48%
Female 11 52%
Presentation status
Primary tumor 15 71%
Local recurrence 6 29%
Histologic diagnosis
Liposarcoma 11 52%
Leiomyosarcoma 4 19%
Malignant fibrous histiocytoma 3 14%
Synovial sarcoma 2 10%
Angiosarcoma 1 5%
Tumor localization
Thigh 16 76%
Groin 5 24%
Tumor grade
Low 3 14%
Intermediate 5 24%
High 13 62%
Vessel infiltration
Artery 1 5%
Vein 4 19%
Artery and vein 4 19%
No 12 57%
*Median tumor size was 10.5 cm (range, 4-24 cm).rofemoral replacement in three patients was performed byusing autologous vein (n  2) or ePTFE (6 mm; n  1)
prostheses. In the latter reconstructions, the deep femoral
artery was reconnected to the axial bypass with a segment of
reversed GSV (n  2) or was ligated (n  1). Femoropop-
liteal bypasses above the knee were implanted in ten pa-
tients. Six of these patients received ePTFE prostheses (6
mm), three patients were treated by reversed GSV, and in
one case a Dacron bypass graft (6 mm) was used. One
autologous femoropopliteal graft ended at the level of the
knee joint, and one femoropopliteal ePTFE prosthesis (6
mm) ended below the knee joint. In 19 patients, anatomic
reconstructions were performed. Autologous grafts con-
sisted of contralateral GSV (n 6) and ipsilateral GSV (n
2). GSV was implanted in the reverse direction (Table II).
Venous reconstruction. Venous reconstructions
consisted of three iliofemoral and nine femorofemoral/
popliteal reconstructions. For proximal iliofemoral recon-
struction, ePTFE prostheses (8 or 12 mm, n  2) or
autologous venous grafts (GSV, n  1) were used. In the
latter cases, the deep femoral vein was ligated. Four femo-
rofemoral bypasses were implanted by using either ePTFE
prostheses (8 mm, n  2 and 10 mm, n  1) or ipsilateral
autologous GSV. In one of these patients, the deep femoral
vein was ligated. Another five venous reconstructions were
performed in the femoropopliteal region above the knee.
For these procedures, ePTFE prostheses were used (8 mm,
n 2; 10mm, n 1; or 12mm, n 2). A resected femoral
vein was ligated in six patients in whom it was possible to
preserve a functional GSV during sarcoma resection (Table
II).
Follow-up. Patients were seen regularly during the
observation period in our outpatient clinic. The standard
follow-up was at 6 weeks and 6 months after surgery and
Table II. Treatment type in 21 patients with soft tissue
sarcomas of the lower extremity involving major vascular
structures
Characteristics No. (N  21) %
Resection type
CR with negative margin 14 66%
CR with positive margin 5 24%
ICR 2 10%
Vascular replacement
Artery 8 40%
Vein 0 0
Artery and vein 12 60%
Arterial reconstruction 20 100%
Vein/ePTFE/Dacron 8/10/2 40%/50%/10%
Venous reconstruction 12 60%
Vein/ePTFE 2/10 17%/83%
Adjuvant treatment
Only surgery 8 38%
Surgery  IORT  ERT 7 33%
Surgery  IORT-ERT 4 19%
Surgery  ERT 2 10%
CR, Complete resection; ICR, incomplete resection; ePTFE, expanded
polytetrafluoroethylene; IORT, intraoperative radiotherapy; ERT, external
radiotherapy.yearly thereafter. Patients were questioned about symp-
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discomfort. Clinical examinations were usually combined
with duplex sonography. In addition, patients were seen
according to the routine oncologic follow-up schedule. To
evaluate the outcome and patient acceptance of the limb-
preserving operation, the following data were gathered at
the most recent assessment. (1) Patients were asked their
opinion about the surgical result (categories: excellent,
good, and poor); (2) patients were asked whether they
would have preferred amputation (categories: amputation
or limb salvage); and (3) limb function was assessed by
using the Enneking system for reconstructive procedures
after surgical treatment of tumors of the musculoskeletal
system.33
Statistical analysis. SAS software (release 9.1; SAS
Institute, Inc, Cary, NC) was used for statistical analysis.
The distribution of age at operation, tumor size, and fol-
low-up time were described as median with IQR. Kaplan-
Meier estimations were used to analyze the rates of patency,
limb salvage, and local tumor control; the metastasis-free
period; and overall survival from the date of operation.34
The 2- and 5-year rates with a corresponding 95% confi-
dence interval (CI) are presented for each end point. Pa-
tients in whom no event was observed for one of the end
points were censored at the last follow-up and are indicated
in the figures as a vertical line. The end of the follow-up
period for all patients alive was in February 2004. One
patient was lost to follow-up 23months after operation and
was included as a censored observation. The log-rank test
was performed to compare survival time distributions be-
tween curves regarding tumor grade, margin of resection,
and vessel infiltration. Cox proportional hazards regression
analysis35 was performed to analyze the multivariate effect
on overall survival of the factors tumor grade, margin of
resection, and vessel infiltration. The estimated hazard
ratios were given. Two-sided P values were always com-
puted, and an effect was considered statistically significant
at P  .05.
RESULTS
Resectability and vascular infiltration. All tumors
could be resected without amputation. In all, 19 (90%) of
20 patients were treated by complete en bloc resection for
locally advanced STS without concomitant metastatic dis-
ease (Table II). Vascular resection was performed for 17
(81%) type I, 3 (14.3%) type II, and 1 (4.7%) type III STS
(Fig 1). Histopathologic examination of the specimens
showed that blood vessels had been infiltrated in 43% of the
STS. Four (19%) specimens showed both arterial and ve-
nous infiltration, four (19%) specimens showed venous
infiltration, and one (5%) specimen showed arterial infiltra-
tion (Table I). Involvement of major nerves was observed
in nine (42.8%) patients. Of these, the femoral nerve was
partially resected in six patients, and the sciatic nerve was
partially resected in three patients. Involvement of nerves
was diagnosed only in patients with type I STS (53%).
Morbidity and mortality. Surgical morbidity during
the hospital stay developed in 12 (57.2%) of 21 patients.The most common complications observed were soft tissue
and skin necrosis, hematoma, and lymphatic fistula (Table
III). Seven (33%) patients required operative reinterven-
tion. Most patients with wound complications were treated
conservatively (57%), as were half of the patients with
postoperative hematoma. At the 17th postoperative day,
one above-knee ePTFE bypass had become occluded be-
cause of a technical failure and had to be replaced. One
massively obese woman died 12 days after surgery of a fatal
pulmonary embolism (mortality 5%). After discharge from
the hospital, bypass infections were seen in four patients
(19%). These infections were diagnosed 1.5, 2, 4, and 5
months after surgery. In these patients, vascular replace-
ment was performed for three type I and one type II STS.
The infected material included ePTFE (n  2), Dacron (n
 2), and vein (n 1). All patients were successfully treated
by limb-preserving reoperation. One patient had an in-
fected venous ePTFE prosthesis and an uninfected arterial
GSV graft. The treatment consisted of explantation of the
infected ePTFE graft. Another patient presented with an
infected arterial and venous ePTFE prosthesis. Subse-
quently, the graft was explanted, and the arterial bypass was
replaced. Another patient had an infected venous Dacron
graft and an infected arterial GSV bypass that necessitated
explantation. Another patient was successfully treated by
operation for a type II STS in which an infected Dacron
graft was replaced by an autologous graft.
Arterial resection and graft function. Twenty
(95.2%) of 21 patients showed arterial involvement. Arte-
rial reconstructions were performed in all patients with
resections for type I, or II, or III disease. Synthetic grafts
were used in 12 reconstructions (60%). Median follow-up
was 34 months for surviving patients (IQR, 20-62
months). Seven (35%) arterial bypass occlusions were ob-
served in 20 reconstructions. The primary 2- and 5-year
patency rates of arterial reconstructions were 58.3% and
Table III. Morbidity, reoperation rate, and mortality in
21 patients with lower extremity soft tissue sarcoma
involving major vascular structures
Variable Total (N  21) %
Morbidity (hospital)
Surgical morbidity 12 57.2%
Soft tissue/skin necrosis 5
Hematoma 4
Wound infection 2
Graft thrombosis 1
Lymphatic fistula 3
Nerve damage (peroneal paresis) 1
Reoperation 7 33%
Bypass revision 2
Wound revision 3
Hematoma revision 2
Medical morbidity 1 4.8%
Pulmonary embolism 1
Mortality (hospital)* 1 4.8%
*Fatal pulmonary embolism.58.3%, respectively (2- and 5-year 95% CI: 31.5%-77.8%
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served in autologous and prosthetic bypasses. Specifically,
thrombosis developed in 3 (37.5%) of 8 venous bypasses
(femoropopliteal GSV grafts) and 4 (33.3%) of 12 pros-
thetic reconstructions (femoropopliteal ePTFE grafts). By-
pass revision was performed in two patients, bypass replace-
ment in three patients, and graft explantation in one
patient. One patient with an asymptomatic femoropopliteal
bypass occlusion 16 months after surgery was treated con-
servatively. The secondary 2- and 5-year patency rates of
arterial reconstructions were 78.3% and 78.3%, respectively
(5 events, 25%; 2- and 5-year 95% CI: 51.9%-91.3% and
51.9%-91.3%, respectively; Fig 2).
Venous resection and graft function. Among all 21
patients, 18 (85.7%) were treated by venous resection: 17
(81%) for type I involvement and 1 (4.8%) for type III
involvement. Of type I resections, 12 (70.5%) were treated
by venous replacement. The vein was not reconstructed in
one patient with a type III resection. Thus, of 18 patients in
whom venous resections were performed, veins were recon-
structed only in 12 (66.6%). Most of the patients received
prosthetic grafts (ePTFE prostheses, n  10; GSV, n  2)
to replace the resected veins. A patent venous reconstruc-
tion was found in seven (58.3%) patients, whereas venous
occlusions occurred in five (41.7%) patients. The primary
and secondary venous patency after 2 and 5 years was 54.9%
and 54.9%, respectively (2- and 5-year 95% CI: 18.7%-
80.6%; Fig 3). The median interval until venous thrombosis
was observed was 12 months (range, 1.7-64 months).
None of these patients required operative or interventional
treatment. Venous thrombosis was clinically asymptomatic
or presented with well-tolerated edema.
Limb salvage and limb function. The 2- and 5-year
limb-salvage rate was 94.1% (one event, 5%; 2- and 5-year
95% CI: 65%-99.2%; Fig 4). One patient required hemipel-
vectomy because of local recurrence in the proximal thigh
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Fig 2. Primary and secondary arterial patency in 20 patients with
resection of soft tissue sarcoma and major arteries in the lower
limb. The median follow-up was 34 months (interquartile range,
20-62 months). Censored patients are marked (as a vertical line);
patients at risk and the 95% confidence interval (CI) are shown.12 months after surgery. In all patients in whom arterialocclusion occurred during the observation period, ischemic
limb loss was prevented by reoperation (except for one
patient, who was treated conservatively). Nine (42.8%) of
21 patients were interviewed and evaluated regarding limb
function. Concerning the acceptance of the surgical result,
five patients thought that the result was excellent, three
patients thought that the result was good, and one patient
thought that the result was poor (because of a muscular
contracture that impaired walking). None of the patients
interviewed would have preferred primary amputation in-
stead of the limb-sparing operation with vascular replace-
ment. With the Enneking score (with a maximum of 5
points), pain was assessed with an average of 4.2 points,
function with an average of 2.9 points, emotional accep-
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Fig 3. Primary and secondary venous bypass patency in 12 pa-
tients who underwent resection of soft tissue sarcoma and major
deep veins in the lower limb. Themedian follow-up was 34months
(interquartile range, 20-62 months). Censored patients are
marked (as a vertical line); patients at risk and the 95% confidence
interval (CI) are shown.
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Fig 4. Limb-salvage rates in 20 patients who underwent vascular
reconstruction during soft tissue sarcoma surgery in the lower
limb. The median follow-up was 34 months (interquartile range,
20-62 months). Censored patients are marked (as a vertical line);
patients at risk and the 95% confidence interval are shown.tance with an average of 3.3 points, support (brace, cane, or
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an average of 3.7 points, and gait with an average of 3.1
points. Taken together, all patients achieved an average of
20.9 points, which is an average of 69.6%.
Tumor control and survival. During follow-up, 3
(15.8%) of 19 patients who were treated by complete
tumor resection developed local recurrence. The 2- and
5-year local tumor control rates of these patients were
93.8% and 80.4% (2- and 5-year 95% CI: 63.2%-99.1% and
37.6%-95.2%, respectively; Fig. 5). At last follow-up, 11
(52.4%) patients had died. The 2- and 5-year overall sur-
vival rates were 70.4% and 52.0%, respectively (2- and
5-year 95% CI: 45.5%-85.5% and 27.3%-71.9%, respec-
tively; Fig 5). Nine patients (47.4%) died because of hema-
togenous metastatic disease after complete resection. The
2- and 5-year metastasis-free survival rates were 63.6% and
37.7% (2- and 5-year 95% CI: 36.0%-81.8% and 13.8%-
62.5%, respectively; Fig 5). Univariate analysis determined
vessel infiltration at histopathologic examination (positive
vs negative, P  .0027), tumor grade (high grade vs
intermediate grade and low grade, P .0266), and margin
of resection (complete resection with clear margin vs com-
plete resection with positive margin, P  .0215) to be
significant prognostic factors for survival. By multivariate
analysis, high tumor grade (P  .0439) and blood vessel
infiltration (P  .0124) were confirmed as significant risk
factors associated with an increased risk of death (hazard
ratios of 5.914 and 13.002, respectively; Fig 6).
DISCUSSION
Limb-preserving resection is recommended for patients
with STS of the lower extremity.1-8 Locally advanced STS
involving major vascular or neural structures are also con-
sidered as an indication for limb salvage.23-28,36,37 With
modern surgical techniques, STS can be resected en bloc
together with affected neurovascular structures.26 The first
description of sarcoma resection in the extremities with
subsequent arterial replacement was reported by Fortner et
al17 in 1977. In addition, Fortner et al17 and Imparato et
al18 described venous replacement during limb-sparing sur-
gery.
The importance of vascular involvement by extremity
STS has been underestimated. In this analysis, blood vessels
were affected in almost 10% of all adult patients who were
treated for lower limb STS at our institution during the
study period. In a review of the literature, blood vessel
involvement was reported in only 5% of the cases.23,28 Most
of the clinical series, however, are not representative be-
cause not all patients undergoing operation for extremity
STS during the periods studied were analyzed.17-27 Fur-
thermore, several investigators did not specifically focus on
the histopathologically well defined tumor entity of adult
STS but included other malignancies, such as carcinoma,
sarcoma of the bone (osteosarcoma and Ewing’s sarcoma),
and benign lesions (Table IV).17,18,21,22,28 From an onco-
logic point of view, there is little use in reporting tumor
control and survival in such an eclectic groups of patients.
These findings hamper the interpretation of the clinicalresults and comparability of different studies. Furthermore,
only two series reported on more than ten patients with
extremity STS, and only one of these analyses was restricted
to the lower extremity.23,26 This series is the largest series
of a consecutive group of adult patients with lower limb
STS analyzed to date for vascular involvement. Another
aspect underlining the importance of oncologic vascular
surgery in patients with extremity STS is the considerable
number of specimens in this analysis with histopathologi-
cally proven sarcoma infiltration of the blood vessel wall.
Infiltrative growth was found to affect not only arteries and
veins together, but also arteries or veins alone. Until now,
this important clinical feature of extremity STS has been
evaluated by only a few investigators.26,28 Not only the
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Fig 5. Local tumor control, survival, and metastasis-free survival
after complete resection with vascular reconstructions in 19 pa-
tients for lower-limb extremity soft tissue sarcoma. The median
follow-up was 34 months (interquartile range, 20-62 months).
Censored patients are marked (as a vertical line); patients at risk
and the 95% confidence interval are shown.
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Fig 6. Survival according to vessel infiltration after complete re-
section with vascular reconstructions in 19 patients for lower-limb
extremity soft tissue sarcoma. The median follow-up was 34
months (interquartile range, 20-62 months). Censored patients
are marked (as a vertical line); patients at risk and the 95% confi-
dence interval are shown.necessity of vascular en bloc resection and repair, but also
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ing a treatment algorithm, is indicated by this finding. The
decision of whether or not to resect blood vessels and to
what extent depends on preoperativeMR/CT imaging and
intraoperative findings.17,18,26,38 MR angiography might
be augmented by conventional angiography or duplex
sonography. The value of positron emission tomography is
unclear.39
Using standard radiologic diagnostic procedures such as
MR or CT imaging, we have suggested a four-stage classifica-
tion that describes the growth pattern of extremity STS with
respect to the major vascular structures of the limbs. Patients
with a type I STS (blood vessel involvement of artery and vein)
require arterial reconstruction after en bloc resection, whereas
venous repair depends on the collateral venous drainage. If
sufficient collateral venous drainage is preserved, then venous
reconstruction is not necessary. Patients in whomonly arteries
are affected by the STS (type II involvement) regularly require
blood vessel replacement after tumor clearance. Those with a
Table IV. Review of the literature: Clinicopathological da
sarcoma involving major blood vessels
Reference
Years
studied
No.
Patients
Tumor
type
Fortner 197717 1955-1976 7 5 STS
1 CA
1 benign
Imparato 197818 1967-1976 13 9 STS
4 OS
Nambisan 198619 1977-1985 10 10 STS 
Ohara 199120 2 2 STS 
Wuisman 199421 12 11 OS
1 ES
Koperna 199622 1984-1992 14 5 STS
8 OS
1 ES
Karakousis 199623 1979-1994 21 21 STS 
Kawai 199624 1982-1994 8 8 STS 
Reix 199825 1985-1995 7 7 STS 
Hohenberger 199926 1984-1992 20 20 STS
Bonardelli 200027 1995-1999 7 7 STS 
Present series 2004 1988-2003 21 21 STS
STS, Soft tissue sarcoma; BP, bypass; ePTFE, expanded polytetrafluoroethyle
local recurrence; DR, distant recurrence; PT, primary tumor.
*Five-year-survival rate.
**Absolute number of survivors.type III STS (involvement of a vein) will benefit from venousreconstruction if sufficient collateral venous drainage has not
been maintained. Type IV, by far the most common type of
STS in the extremities, does not require blood vessel replace-
ment because an adequate margin can be obtained without
vascular resection. We present our algorithm in Fig 1.
In the iliofemoral and femoropopliteal region above
the knee, we used predominantly synthetic grafts for arte-
rial reconstruction. The rationale for this was to reduce the
operative time and to preserve the ipsilateral GSV. Alterna-
tively, autologous vein grafts, such as the GSV, from the
contralateral leg can be used.17,23,26 If the superficial and
deep femoral arteries were affected by the STS, we recon-
structed both. In patients with distal arterial reconstruc-
tions, autologous bypasses were preferred. Venous repair
has to be performed according to the functional integrity of
the ipsilateral GSV. If the ipsilateral GSV was preserved and
was patent, then the remaining femoral vein stumps were
ligated.26 However, if the GSV was not functioning (scle-
rosis) or was absent or resected together with the femoral
d clinical results of surgery in lower extremity soft tissue
er-
e
or
Tumor
size (cm) PT/LR
Type of STS
(resected
vessels) Graft location
7 # 6 type I
1 type II
2 iliac
5 femoral
5-15 # 13 type I 11 femoropopliteal
2 subclavian
 # # 7 type I
3 type II
3 iliac
4 iliofemoral
2 femoropopliteal
1 crural
# 2/0 2 type III 2 femoral
# # 12 type I 12 popliteal
# # 6 type I
1 type II
7 type III
2 iliofemoral
10 femoropopliteal
2 popliteal
 9.4 17/4 8 type I
13 type II
7 iliofemoral
13 femoropopliteal
1 subclavian
# 8/8 8 type I 6 femoral
2 popliteal
5 7/0 7 type III 7 femoral
# 15/5 11 type I
8 type II
1 type III
6 iliofemoral
1 femorofemoral
9 femoropopliteal
3 popliteopopliteal
 # 5/2 4 type I
2 type II
1 type III
4 femoropopliteal
10 15/6 17 type I
3 type II
1 type III
4 iliofemoral
1 iliocrural
3 femorofemoral
12 femoropopliteal
not specified; OS, osteosarcoma; ES, Ewing’s sarcoma; CA, carcinoma; LR,ta an
High
grad
tum
#
#
80%
# 
#
#
86%
# 
# 
90%
85%
86%
ne; #,vein, then reconstruction was performed. Venous repair in
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ciated clinical sequelae (complicated wound healing, pain,
swelling, tension, and skin alterations).17,26 In our series, a
long-term venous patency of 54.9% was observed with
predominantly ePTFE grafts. Because of rapid formation of
collateral drainage, an occlusion of a venous bypass occur-
ring some weeks after surgery usually did not require oper-
ative revision.26 The use of the autologous vein has not
proven to be superior to synthetic grafts with respect to the
long-term patency rate after limb-salvage surgery.17,18,21
The results with respect to limb salvage were excellent
in this study. Comparably high salvage rates have been
reported before, ranging from 80% to 100% (Table
IV).17,23,26 Surviving patients at the latest follow-up in our
study gave a good overall assessment of limb function and
showed good results after being classified by the Enneking
score.33 None of these patients would have preferred pri-
mary amputation instead of limb-preserving resection with
Table IV. Continued.
Arterial repair Venous repair
Follow-up
(mo)
Arterial/venou
patency
2 venous BP
2 Dacron BP
3 ligation
3 venous BP
3 ligation
# 4/4 (100%)/
3/3 (100%)
13 venous BP 3 venous BP 46 12/13 (92%)/
1/3 (33%)
1 venous BP
6 ePTFE BP
3 Dacron BP
6 ePTFE BP 24.8 9/10 (90%)/
2/6 (33%)
None 2 ePTFE BP # #
1/2 (50%)
12 venous BP 12 venous BP # 11/12 (92%)/
10/12 (83%)
7 venous BP 8 venous BP
1 Dacron BP
4 ePTFE BP
55 6/7 (86%)/
10/13 (77%)
4 venous BP
17 ePTFE BP
1 venous BP
2 ePTFE BP
5 ligation
31 #/#
4 venous BP
4 Dacron BP
2 venous BP
5 ePTFE BP
1 ligation
42.5 5/8 (63%)/
2/7 (29%)
subad. dissection 2 venous patch
5 ligation
36.4 #/#
8 venous BP
11 ePTFE BP
6 venous BP
4 ePTFE BP
1 anastomosis
19/19 (100%)
9/10 (90%)
2 venous BP
2 ePTFE BP
3 subad. dissection
3 venous BP
2 transposition
25 4/4(100%)/
5/5 (100%)
8 venous BP
10 ePTFE BP
2 Dacron BP
2 venous BP
10 ePTFE BP
6 ligation
34 15/20 (75%)/
7/12 (58%)vascular replacement. Furthermore, all of these patientswere satisfied with the functional result. Compared with
the studies available, we report the important criterion of
functionality after limb-preserving resection with vascular
replacement.17-27 However, we do acknowledge that limb-
function assessment was based on a small number of pa-
tients.
During observation, the overall local tumor control was
high in this series (86%).Comparably high rates of local tumor
control, ranging from 80% to 100%, were reported in the few
studies that consisted of more than five patients.18,19,23-26
The use of adjuvant radiation therapy in patients with limb-
sparing surgery for extremity STS has been widely accepted.4,5
We selectively apply combined intraoperative radiotherapy
with postoperative boost radiotherapy for extremity STS in
high-risk patients or deliver postoperative radiotherapy.31,32
Data from our observational analysis and data from the liter-
ature show that intraoperative radiotherapy improves local
tumor control.31,32 The high local control after limb-sparing
Limb-salvage
(primary/
secondary)
Morbidity/
mortality LR/DR Survival
/7 (100%)/
/7 (71%)
4/7 (57%)/
0/7 (0%)
2/7 (29%)/
2/7 (29%)
86%*
1/13 (85%)/
0/13 (77%)
1/13 (8%)/
#
2/13 (15%)/
5/13 (38%)
8/13(62%)**
/10 (90%)/
/10 (80%)
6/10 (60%)/
#
0
6/10 (60%)
6/9 (67%)**
/2 (100%)/
/2 (100%)
2/2 (100 %)/
#
0
#
2/2 (100%)**
0/12 (83%)/
0/12 (83%)
6/12 (50%)/
0/12 (0%)
0
0
12/12
(100%)**
/# 7/14 (50%)/# 0
6/14 (43%)
57%*
0/21 (95%)/
0/21 (95%)
7/21(33%)/
0/21 (0%)
3/21 (14%)/
8/21 (38%)
63%*
/8 (75%)/
/8 (75%)
2/8 (25%)/# 0
2/8 (25%)
8/8
(100%)**
/7 (100%)/
/7 (100%)
0/7 (0%)/
0/7 (0%)
1/7 (14%)/
4/7 (57%)
3/7 (43%)**
9/20 (95%)/
9/20 (95%)
7/20 (35%)/
1/20 (5%)
4/20 (20%)/
11/20 (55%)
40%*
/7 (100%)/
/7 (100%)
1/7 (14%)/
0/7 (0%)
0
2/7 (29%)
5/7 (71%)**
1/21
100%)/
0/21 (95%)
12/21 (57%)/
1/21 (4.8%)
3/21 (14%)/
10/21 (48%)
52%*s
7
5
1
1
9
8
2
2
1
1
#
2
2
6
6
7
7
/ 1
1
7
7
2
(
2surgery combined with adjuvant local treatment and the re-
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limb-salvage rates in extremity STS involving major blood
vessels (Table IV).
The goals of limb salvage and reasonable functional
results must be evaluated in the light of the high rate of
perioperative morbidity, which seems to be related specifi-
cally to these procedures.17,19,20,22 Hematoma, wound
infection, skin and soft tissue necrosis, and lymphatic fistu-
las are the major causes of a complicated postoperative
course.17,19,20,22 Cautious interpretation, however, is
mandatory because en bloc resection alone without vascu-
lar repair or intraoperative adjuvant treatment modalities
has shown a wound morbidity rate of 34.7%.40,41 Here, a
long procedural exposure time, the use of prosthetic mate-
rial, and manipulation as a result of adjuvant intraoperative
treatment (radiotherapy, brachytherapy, or regional che-
motherapy) are possible risk factors for the development of
complications. The question of whether synthetic material
influences morbidity cannot be answered because of the
small number of patients studied so far. Nevertheless, asep-
tic procedural standards, the correct placement of suction
drains, and prophylactic administration of antibiotics
(cephalosporin) are recommended. Careful hemostasis and
cautious administration of heparin are mandatory to reduce
bleeding complications. Because patients do not experience
peripheral arterial disease and usually have an excellent
peripheral runoff, low-dose heparinization is sufficient for
vessel replacement at the iliofemoral level.28
Concerning patient survival, this study shows that a
stage-dependent long-term survival can be achieved. The
2- and 5-year survival rates of 74.1% and 54.7% in this
selective high-risk group of STS patients in this series are
respectable and comparable to the results of Hohenberger
et al26 and Karakousis et al.23 With respect to the survival
rates, most patients in these studies had at least three
adverse prognostic factors as diagnosed from the local
tumor growth (higher tumor grade [intermediate grade
and high grade tumors], subfascial location, and expansive
growth).2,6-8,23,26,29 It has now been shown that his-
topathologically proven infiltrative growth is a negative
predictor for survival at univariate and multivariate analysis.
This pivotal issue calls for further clinical investigation
considering the high risk for distant recurrence and subse-
quent tumor-related death. Nevertheless, even in the light
of the high risk for distant recurrence, whether adjuvant
chemotherapy should be given remains an individual and
interdisciplinary decision.42
In this study, we demonstrated the clinical significance
of surgical resection in patients with extremity STS involv-
ing major blood vessels. A novel classification system and a
treatment algorithm have been described. Vascular replace-
ment enables a limb-sparing resection with excellent local
tumor control, acceptable limb function, and stage-depen-
dent oncologic long-term results.
We thank Sherryl Sundell for her help preparing this
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